Lack Of Data Released From Merck/Schering-Plough Vytorin Trial Spurs House Inquiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies also reject expert panel recommendation to change the primary endpoint for the ENHANCE trial.